AVANOS MEDICAL INC (AVNS) Stock Fundamental Analysis

NYSE:AVNS • US05350V1061

13.99 USD
+0.01 (+0.07%)
At close: Mar 3, 2026
13.99 USD
0 (0%)
After Hours: 3/3/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall AVNS gets a fundamental rating of 4 out of 10. We evaluated AVNS against 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AVNS get a neutral evaluation. Nothing too spectacular is happening here. AVNS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year AVNS was profitable.
  • In the past year AVNS had a positive cash flow from operations.
  • In multiple years AVNS reported negative net income over the last 5 years.
  • In the past 5 years AVNS always reported a positive cash flow from operatings.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • AVNS has a better Return On Assets (-6.79%) than 65.76% of its industry peers.
  • AVNS's Return On Equity of -9.37% is fine compared to the rest of the industry. AVNS outperforms 68.48% of its industry peers.
  • With a decent Return On Invested Capital value of 1.47%, AVNS is doing good in the industry, outperforming 67.93% of the companies in the same industry.
  • AVNS had an Average Return On Invested Capital over the past 3 years of 1.82%. This is significantly below the industry average of 8.75%.
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROIC 1.47%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • AVNS has a better Operating Margin (2.41%) than 67.93% of its industry peers.
  • AVNS's Operating Margin has declined in the last couple of years.
  • AVNS has a Gross Margin of 50.47%. This is comparable to the rest of the industry: AVNS outperforms 46.74% of its industry peers.
  • AVNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.41%
PM (TTM) N/A
GM 50.47%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AVNS is destroying value.
  • AVNS has more shares outstanding than it did 1 year ago.
  • AVNS has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AVNS has been reduced compared to a year ago.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • AVNS has an Altman-Z score of 1.22. This is a bad value and indicates that AVNS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of AVNS (1.22) is comparable to the rest of the industry.
  • AVNS has a debt to FCF ratio of 2.33. This is a good value and a sign of high solvency as AVNS would need 2.33 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.33, AVNS belongs to the top of the industry, outperforming 86.41% of the companies in the same industry.
  • AVNS has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.12, AVNS is in the better half of the industry, outperforming 63.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Altman-Z 1.22
ROIC/WACC0.15
WACC9.85%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • AVNS has a Current Ratio of 2.15. This indicates that AVNS is financially healthy and has no problem in meeting its short term obligations.
  • AVNS has a Current ratio (2.15) which is in line with its industry peers.
  • AVNS has a Quick Ratio of 1.26. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of AVNS (1.26) is worse than 65.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.26
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for AVNS have decreased strongly by -25.40% in the last year.
  • The Earnings Per Share has been growing slightly by 3.80% on average over the past years.
  • The Revenue has been growing slightly by 1.95% in the past year.
  • The Revenue has been decreasing by -0.38% on average over the past years.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.51% on average over the next years. This is quite good.
  • AVNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.19% yearly.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.88, which indicates a correct valuation of AVNS.
  • Based on the Price/Earnings ratio, AVNS is valued cheaply inside the industry as 88.59% of the companies are valued more expensively.
  • AVNS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.83.
  • A Price/Forward Earnings ratio of 13.70 indicates a correct valuation of AVNS.
  • Based on the Price/Forward Earnings ratio, AVNS is valued cheaper than 90.22% of the companies in the same industry.
  • AVNS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 14.88
Fwd PE 13.7
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • AVNS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AVNS is cheaper than 88.04% of the companies in the same industry.
  • AVNS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AVNS is cheaper than 95.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.09
EV/EBITDA 11.84
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AVNS's earnings are expected to grow with 16.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.73
PEG (5Y)3.91
EPS Next 2Y16.51%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVANOS MEDICAL INC

NYSE:AVNS (3/3/2026, 8:04:00 PM)

After market: 13.99 0 (0%)

13.99

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners96.89%
Inst Owner Change27.64%
Ins Owners2.95%
Ins Owner Change-0.82%
Market Cap650.53M
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %6.62%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.91%
EPS NQ rev (3m)3.91%
EPS NY rev (1m)0%
EPS NY rev (3m)5.2%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.65%
Valuation
Industry RankSector Rank
PE 14.88
Fwd PE 13.7
P/S 0.93
P/FCF 15.09
P/OCF 8.71
P/B 0.84
P/tB 2.45
EV/EBITDA 11.84
EPS(TTM)0.94
EY6.72%
EPS(NY)1.02
Fwd EY7.3%
FCF(TTM)0.93
FCFY6.63%
OCF(TTM)1.61
OCFY11.48%
SpS15.08
BVpS16.74
TBVpS5.71
PEG (NY)1.73
PEG (5Y)3.91
Graham Number18.81
Profitability
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROCE 1.86%
ROIC 1.47%
ROICexc 1.63%
ROICexgc 4.36%
OM 2.41%
PM (TTM) N/A
GM 50.47%
FCFM 6.15%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Debt/EBITDA 1.62
Cap/Depr 81.23%
Cap/Sales 4.51%
Interest Coverage 2.6
Cash Conversion 133.87%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.26
Altman-Z 1.22
F-Score6
WACC9.85%
ROIC/WACC0.15
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


Can you provide the profitability details for AVANOS MEDICAL INC?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for AVNS stock?

The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to grow by 8.62% in the next year.